Retatrutide: Triple Receptor Agonism in Next-Generation Obesity and Metabolic Research
Research Use Only. This article is for scientific and educational reference only. All products are sold for research purposes and are not intended for human or animal consumption.
Overview
Retatrutide (CAS 2381090-02-2) represents the next frontier in incretin-based metabolic research — a synthetic peptide engineered to simultaneously activate three receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. This triple receptor co-agonism, sometimes referred to as a "triagonist" approach, is designed to leverage the complementary metabolic effects of all three incretin and glucagon pathways.
Developed by Eli Lilly and Company, retatrutide has advanced through Phase 2 clinical trials with results that have attracted significant attention in the metabolic research community. Its molecular weight is approximately 4,859 Da, and it is administered as a once-weekly subcutaneous injection in clinical protocols.
Mechanism of Action
The three receptor targets of retatrutide each contribute distinct physiological effects. GLP-1 receptor activation reduces appetite, slows gastric emptying, stimulates glucose-dependent insulin secretion, and suppresses glucagon. GIP receptor activation potentiates insulin secretion and appears to modulate adipose tissue metabolism and central appetite circuits. Glucagon receptor activation increases hepatic glucose output and, critically, stimulates energy expenditure through thermogenesis and lipolysis — an effect that counterbalances the weight-promoting potential of glucagon in isolation.
The combination of GLP-1-mediated appetite suppression, GIP-mediated metabolic modulation, and glucagon-mediated energy expenditure creates a multi-pronged approach to energy balance that preclinical models suggest may be more effective than dual or single receptor approaches. The peptide's fatty acid modification enables albumin binding and supports its extended half-life for once-weekly dosing.
Key Research Findings
Phase 2 data published in the New England Journal of Medicine in 2023 reported that retatrutide at 12 mg produced a mean weight reduction of 24.2% from baseline over 48 weeks in adults with obesity. This represented the largest weight reduction reported for any pharmacological agent in a randomized controlled trial at the time of publication, exceeding the 22.5% observed with tirzepatide in the SURMOUNT-1 trial over a longer 72-week period.
Retatrutide also demonstrated significant reductions in waist circumference, triglycerides, and blood pressure. Dose-dependent improvements in glycemic parameters were observed across all dose groups. The Phase 2 trial enrolled participants with BMI ≥27 with at least one weight-related comorbidity, and the 12 mg dose achieved ≥20% weight loss in approximately 83% of participants.
Phase 3 trials (TRIUMPH program) are currently underway and will provide longer-term safety and efficacy data, including cardiovascular outcomes.
Chemical Properties
| Property | Value | |---|---| | CAS Number | 2381090-02-2 | | Receptor Targets | GIP, GLP-1, Glucagon | | Molecular Weight | ~4,859 Da | | Form | Lyophilized powder | | Purity (research grade) | ≥99% HPLC | | Storage | −20°C, protect from light |
Research Considerations
As a triple receptor agonist, retatrutide's research profile includes considerations not present with dual or single agonists. The glucagon receptor component introduces hepatic effects that require monitoring in metabolic research protocols. Gastrointestinal adverse events have been reported in clinical trials, consistent with the GLP-1 receptor agonist class. Retatrutide is supplied as a lyophilized powder for research use and requires reconstitution with bacteriostatic water.
Research Use Only. This article is for scientific and educational reference. All products are sold for research purposes only and are not intended for human or animal consumption.